Even though studies have shown that mutations in the PCLO gene could be involved in GBM growth and survival [39], it was removed from the personalisation process as every GBM sample had variants of this genes (Figure 2), making it difficult to link it to drug response. The gene discussed is PCLO; the disease is glioblastoma.